CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 760 enrolled
Drug / intervention
Sample collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04403880
NCT04403880N/ACompleted
CompareCT.gov

Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals

HIV Vaccine Trials Network·observational·Posted May 27, 2020·Updated Jan 12, 2026

In Brief

An observational study evaluating Sample collection for SARS-CoV-2 and COVID-19. Completed, enrolled 760 participants across 53 sites in 6 countries.

Detailed Summary

The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2, COVID-19
CountriesMalawi, Peru, South Africa, United States, Zambia, Zimbabwe
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 27, 2020
Enrollment StartMay 13, 2020
Primary CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.1 years ago

Interventions

Sample collectionother

* Optional nasal specimen(s) * Blood collection